GLP1R and type 2 diabetes mellitus: For example, Lotiglipron, known chemically as PF-07081532, represents a significant breakthrough in the field of GLP-1R agonists, particularly for its efficacy in managing type 2 diabetes; however, phase 2 clinical trials revealed instances of elevated liver enzymes, raising concerns about potential liver toxicity, which led to the discontinuation of the drug development.156